Cabinet nod for India-Uzbekistan MoU on cooperation in pharma sector

New Delhi: The Cabinet Wednesday approved a memorandum of understanding (MoU) to be signed between India and Uzbekistan to increase cooperation in the areas of trade, industry, and research and development of pharmaceutical products. The Cabinet also gave it nod to another MoU between India and Uzbekistan for the establishment of the Uzbek-Indian free pharmaceutical zone in the Andijan region of Uzbekistan.

The MoUs will be signed during the visit of President of Uzbekistan to India on October 1, 2018, an official statement said.

In view of the importance of the growth of the pharma industry in both countries and importance of mutual cooperation in trade, production,research and development in the pharmaceutical sector, both governments have been trying to establish a formal mechanism of bilateral cooperation, it added.

The MoU will explore the possibilities for the production of medicines, including active pharmaceutical ingredients (APIs) in different therapeutic segments in both countries, the statement said.

“It will also exchange information on trade and registration procedures, legal and regulatory requirements for export and import of pharmaceuticals products, including APIs,” it added.

The MoU will increase cooperation with Uzbekistan in the areas of trade, industry and research and development of pharma products, the statement said.

The MoU will facilitate Indian pharmaceutical and biopharmaceutical companies to invest in and establish production facilities in the Uzbek-Indian free pharma zone for manufacture of pharmaceutical products, a separate release said.

  • Related Posts

    WHO launches new primary health care course to strengthen health systems globally

    Health is a human right – yet not everyone can access the health services they need, when and where they need them, without financial hardship. Primary health care (PHC) provides…

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    WHO launches new primary health care course to strengthen health systems globally

    WHO launches new primary health care course to strengthen health systems globally

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert